Biologics & Small Molecules Research
Rapidly perform DOEs to screen optimal assay conditions
The development of biologics-based drugs is an expensive and lengthy process. During early discovery, researchers must select multiple lead candidates, confirm mechanisms of action (MOA) against the target and investigate optimal conditions for production and functional activity before looking into their downstream critical quality attributes (CQAs). The Octet® system provides unmatched ease-of-use and throughput capability in research and assay development for screening and characterization purposes.
Boost your research and commercialization goals by combining BLI and SPR at an attractive promotional price.
The selection of desired antibody-based therapeutics is often based on their binding properties, including binding to FcγRs. Antibodies are sometimes engineered to achieve desired FcγRs binding properties, as their binding can greatly impact their safety and efficacy to both the target and to FcγRs.
Read Application Note
The discovery of small molecule and peptide lead molecules can stem from many sources, including fragment screening, high throughput screening and de novo structural design. Determining and evaluating the affinity of small molecule binding to a therapeutic target is a significant component of the drug discovery process and lead optimization. The hit-to-lead and lead optimization processes are essential to accurately determine biological potency in vitro so structure-activity relationships (SARs) can be used for efficient structural design. Learn how Octet® R series as well as Octet® RH16, Octet® RH96 and Octet® SF3 instruments can be used to characterize small molecule and peptide binding.
Read Technical Note
Phage display is a technique for enabling the study of protein, peptide or DNA interactions with a target protein. This technology enables discovery of high-affinity binders by using bacteriophages to present a target protein on the exterior of the viral coat (while containing the DNA encoding the target protein inside the viral coat). Resulting phages can be screened for binding against a library of peptides or proteins in a high throughput fashion.
Due to its high throughput design, the Octet® BLI system is routinely used as a secondary screening platform for Fab fragments and non-antibody ligands derived from phage display libraries. Such a screen can provide affinity ranking data and estimates of association and dissociation constants for primary hits.
The majority of small molecule inhibitor assays tested with label-free, real-time biosensor technologies are reversible interactions, characterized by commonly used kinetic rate models. However, a significant fraction of therapeutic enzyme inhibitors on the market function through covalent modification of the target.
The Octet® SF3 system is a SPR platform that can be used with regenerable Streptavidin biosensors to reversibly capture protein targets and quantify the efficiency of covalent inhibitors binding to the target. The irreversible inhibitor applications method can be used to determine inhibitor compound's commitment to covalency (Cc) as a metric for irreversible inhibitors.
Competitive compound analysis in drug discovery with novel gradient injections to determine the site specificity of small molecules.
With Octet® BLI Workflows
A comprehensive guide for designing and performing assays that accurately measure the binding kinetics of biomolecular interactions and analyte concen...
Fast, accurate determination of vaccine titre during influenza vaccine manufacture is important in understanding process performance and correctly sca...
Researchers are using the Octet® system to understand the virus's binding mechanisms as a first step in the development of a vaccine
By Octet® Bio-Layer Interferometry (BLI) Platforms
Technologies, Key Considerations, and Applications
For Accurate Determination of Kinetics and Affinity Rate Constants
Tips collected over the years from customers successful with their equipment grant proposals.
Generate high-quality kinetics and affinity data in a fraction of the time compared to standard multi-cycle kinetics using the Octet® SF3.
Monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed
Ideal for high-throughput applications that demand high sensitivity and low sample volume requirements
Get the Latest Updates, Trends and Developments on Label-free, Stress-Free Solutions for Drug Discovery, Biologics Development and Biomanufacturing.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.